<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701727</url>
  </required_header>
  <id_info>
    <org_study_id>Ezetimibe RCT-001</org_study_id>
    <nct_id>NCT00701727</nct_id>
  </id_info>
  <brief_title>Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study</brief_title>
  <official_title>Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiant Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radiant Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, placebo-controlled, cross-over trial comparing the the effects of
      approximately 7 weeks of placebo treatment to 7 weeks of ezetimibe (10mg/day) treatment on
      several parameters of reverse cholesterol transport (RCT) in men and post-menopausal women
      diagnosed with hypercholesterolemia. The primary hypothesis is that the ezetimibe treatment
      will increase the excretion of endogenous (plasma-derived) cholesterol as fecal sterols, with
      secondary hypotheses that there will be a significant increase in de novo cholesterol
      synthesis, treatment will increase cholesterol efflux from tissues into the bloodstream, and
      increase global RCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will compare the effects of approximately 7 weeks of placebo treatment to 7 weeks
      of ezetimibe (10mg/day) on: 1) the efficiency of endogenous (plasma-derived) cholesterol
      excretion (%/day) 2) de novo cholesterol (DNC) synthesis ((%/day) 3) cholesterol efflux from
      tissues into blood (Ra), and 4) global RCT (efflux from tissues that is excreted as fecal
      sterols). Subjects will receive 7 weeks of either treatment or placebo, undergo RCT and DNC
      measurements, taking 10 days, then cross-over to the alternate placebo or treatment for an
      additional 7 weeks, followed by a second set of RCT and DNC measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fecal Excretion of Plasma-derived Cholesterol</measure>
    <time_frame>7 weeks</time_frame>
    <description>(Fecal excretion of plasma-derived cholesterol):The following measurements will be made following isotope infusion:
The composition of fecal neutral and acidic sterols will be measured as % of total.
The excretion rate of fecal neutral and acidic sterols will be measured as mg/day.
The isotopic enrichment of both fecal neutral and acidic sterols will be measured as atomic percent excess (% APE).
Fecal isotope excretion, or recovery, of plasma-derived cholesterol will be calculated as %/day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol, From Fasting Plasma Samples</measure>
    <time_frame>7 weeks</time_frame>
    <description>plasma levels of total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>de Novo Cholesterol Synthesis (DNC)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Plasma DNC will be measured following the isotope infusion of deuterated water, expressed as %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol Efflux Rate (Ra Cholesterol)</measure>
    <time_frame>7 weeks</time_frame>
    <description>The efflux, or mobilization, rate of cholesterol from peripheral tissues into the plasma will be measured as mg/kg/hr. An IV infusion of [13C2] cholesterol mixed in 10% IntralipidÂ® and 10 % ethanol is given piggy-backed into normal saline over 20 hours (4pm - 12 noon). This is used to determine rate of appearance (Ra) cholesterol, which will be measured by dilution of infused [13C2] cholesterol during the plateau phase of plasma enrichment (approximately the last 4 hours of the infusion), as well as to provide the plasma cholesterol that will be traced into biliary sterols.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides (TG)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from baseline in plasma triglycerides, measured in fasting blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density Lipoprotein (LDL);</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from baseline in plasma low-density lipoprotein(LDL), measured in fasting blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density Lipoprotein (HDL)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from baseline in plasma HDL, measured in fasting blood samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ezetimibe (10mg/day)for 7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>1 tablet,10mg, once a day, for 7 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet, once a day, for 7 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male, non-smoker, 21-75 years of age

          -  female, non-smoker, 40-75 years of age

          -  post-menopausal women, as defined by lack of menses for at least 2 years and age &gt;55,
             OR history of documented bilateral oophorectomy, confirmed with an elevated FSH at
             screening

          -  low-density lipoprotein (LDL) concentration between 130-200 mg/dL.

          -  triglyceride (TG) concentration &lt;350 mg/dL, inclusive

          -  high-density lipoprotein (HDL) between 30-60 mg/dL for men and 40 -70 mg/dL for women

          -  ability to give informed consent

        Exclusion Criteria:

          -  Subject has history of diabetes mellitus, active hepatitis, gall bladder disease,
             gastric or ileal bypass surgery, irritable bowel syndrome, and gastrointestinal
             disorder/condition associated with malabsorption, or clinically significant
             abnormalities on screening (prestudy) physical examination of laboratory tests.

          -  Screening laboratory tests with hematocrit &lt;30%, aspartate aminotransferase/alanine
             aminotransferase (AST/ALT) &gt;2*upper limit of normal, abnormal thyroid-stimulating
             hormone (TSH), fasting glucose &gt;=126mg/dL

          -  renal impairment with creatinine clearance (CRCl)&lt;80ml/min

          -  treatment within the last 2 months with drugs known to alter lipid metabolism
             including beta blockers, thiazide diuretics, bile acid resins, statins, ezetimibe,
             niacin, fibrates, plant stanol esters (eg Benecol,phyto sterols) and fishoils

          -  history of known coronary heart disease (CHD), stroke or prior revascularization
             procedure or peripheral vascular disease

          -  history of allergy to egg or soy products

          -  current or recent (past 12 months) of drug abuse or alcohol abuse. Alcohol use must be
             limited to no more than 2 drinks/day (1 drink=12 oz beer, 5 oz wine, or 1.5 oz hard
             liquor). Subject must be willing to avoid large day-to-day fluctuations in alcohol
             intake.

          -  participation in another clinical trial or exposure to any investigational agent
             within 30 days prior to Visit 1

          -  Individual has a condition the Principal Investigator believes would interfere with
             his/her ability to provide informed consent, comply with study instructions, or which
             might confound the interpretation of the study results, or put the subject at undue
             risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Davidson, Md. FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <results_first_submitted>January 10, 2011</results_first_submitted>
  <results_first_submitted_qc>March 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2011</results_first_posted>
  <last_update_submitted>March 14, 2011</last_update_submitted>
  <last_update_submitted_qc>March 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michael H. Davidson, MD, FACC</name_title>
    <organization>Radiant Research</organization>
  </responsible_party>
  <keyword>metabolic diseases</keyword>
  <keyword>metabolic disorder</keyword>
  <keyword>dyslipidemias</keyword>
  <keyword>lipid metabolism disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited at a research clinic, Chicago, IL, from June 2008 to October 2008</recruitment_details>
      <pre_assignment_details>61 subjects screened, 30 subjects excluded(8 failed inclusion criteria, 9 failed exclusion criteria, 3 had unsuitable veins, 5 failed a drug screen, 1 was lost-to-follow-up, 4 were excluded when enrollment was complete), 31 subjects randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe First, Placebo Second</title>
          <description>Ezetimibe first for 7 weeks, followed by placebo for 7 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Ezetimibe Second</title>
          <description>Placebo first for 7 weeks,followed by ezetimibe for 7 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive ezetimibe first and placebo first</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fecal Excretion of Plasma-derived Cholesterol</title>
        <description>(Fecal excretion of plasma-derived cholesterol):The following measurements will be made following isotope infusion:
The composition of fecal neutral and acidic sterols will be measured as % of total.
The excretion rate of fecal neutral and acidic sterols will be measured as mg/day.
The isotopic enrichment of both fecal neutral and acidic sterols will be measured as atomic percent excess (% APE).
Fecal isotope excretion, or recovery, of plasma-derived cholesterol will be calculated as %/day.</description>
        <time_frame>7 weeks</time_frame>
        <population>Per Protocol,all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo daily,7 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10 mg/day 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fecal Excretion of Plasma-derived Cholesterol</title>
          <description>(Fecal excretion of plasma-derived cholesterol):The following measurements will be made following isotope infusion:
The composition of fecal neutral and acidic sterols will be measured as % of total.
The excretion rate of fecal neutral and acidic sterols will be measured as mg/day.
The isotopic enrichment of both fecal neutral and acidic sterols will be measured as atomic percent excess (% APE).
Fecal isotope excretion, or recovery, of plasma-derived cholesterol will be calculated as %/day.</description>
          <population>Per Protocol,all subjects</population>
          <units>mg/day cholesterol excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1593" spread="1287"/>
                    <measurement group_id="O2" value="1950" spread="915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol, From Fasting Plasma Samples</title>
        <description>plasma levels of total cholesterol</description>
        <time_frame>7 weeks</time_frame>
        <population>per protocol, all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo daily,7 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10 mg/day 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol, From Fasting Plasma Samples</title>
          <description>plasma levels of total cholesterol</description>
          <population>per protocol, all subjects</population>
          <units>mg/dL total cholesterol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219" spread="26"/>
                    <measurement group_id="O2" value="187" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>de Novo Cholesterol Synthesis (DNC)</title>
        <description>Plasma DNC will be measured following the isotope infusion of deuterated water, expressed as %.</description>
        <time_frame>7 weeks</time_frame>
        <population>per protocol, all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo daily,7 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10 mg/day 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>de Novo Cholesterol Synthesis (DNC)</title>
          <description>Plasma DNC will be measured following the isotope infusion of deuterated water, expressed as %.</description>
          <population>per protocol, all subjects</population>
          <units>%/day plasma DNC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.1"/>
                    <measurement group_id="O2" value="4.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cholesterol Efflux Rate (Ra Cholesterol)</title>
        <description>The efflux, or mobilization, rate of cholesterol from peripheral tissues into the plasma will be measured as mg/kg/hr. An IV infusion of [13C2] cholesterol mixed in 10% IntralipidÂ® and 10 % ethanol is given piggy-backed into normal saline over 20 hours (4pm â 12 noon). This is used to determine rate of appearance (Ra) cholesterol, which will be measured by dilution of infused [13C2] cholesterol during the plateau phase of plasma enrichment (approximately the last 4 hours of the infusion), as well as to provide the plasma cholesterol that will be traced into biliary sterols.</description>
        <time_frame>7 weeks</time_frame>
        <population>per protocol, all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo daily,7 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10 mg/day 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol Efflux Rate (Ra Cholesterol)</title>
          <description>The efflux, or mobilization, rate of cholesterol from peripheral tissues into the plasma will be measured as mg/kg/hr. An IV infusion of [13C2] cholesterol mixed in 10% IntralipidÂ® and 10 % ethanol is given piggy-backed into normal saline over 20 hours (4pm â 12 noon). This is used to determine rate of appearance (Ra) cholesterol, which will be measured by dilution of infused [13C2] cholesterol during the plateau phase of plasma enrichment (approximately the last 4 hours of the infusion), as well as to provide the plasma cholesterol that will be traced into biliary sterols.</description>
          <population>per protocol, all subjects</population>
          <units>mg/kg/hr cholesterol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.5"/>
                    <measurement group_id="O2" value="4.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides (TG)</title>
        <description>Change from baseline in plasma triglycerides, measured in fasting blood samples</description>
        <time_frame>7 weeks</time_frame>
        <population>per protocol, all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo daily,7 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10 mg/day 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides (TG)</title>
          <description>Change from baseline in plasma triglycerides, measured in fasting blood samples</description>
          <population>per protocol, all subjects</population>
          <units>mg/dL TG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="48"/>
                    <measurement group_id="O2" value="121" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low-density Lipoprotein (LDL);</title>
        <description>Change from baseline in plasma low-density lipoprotein(LDL), measured in fasting blood samples</description>
        <time_frame>7 weeks</time_frame>
        <population>per protocol, all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo daily,7 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10 mg/day 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Low-density Lipoprotein (LDL);</title>
          <description>Change from baseline in plasma low-density lipoprotein(LDL), measured in fasting blood samples</description>
          <population>per protocol, all subjects</population>
          <units>mg/dL LDL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" spread="24"/>
                    <measurement group_id="O2" value="116" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-density Lipoprotein (HDL)</title>
        <description>Change from baseline in plasma HDL, measured in fasting blood samples</description>
        <time_frame>7 weeks</time_frame>
        <population>per protocol, all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo daily,7 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10 mg/day 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>High-density Lipoprotein (HDL)</title>
          <description>Change from baseline in plasma HDL, measured in fasting blood samples</description>
          <population>per protocol, all subjects</population>
          <units>mg/dL HDL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="9"/>
                    <measurement group_id="O2" value="45" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo, 10 mg/day, for 7 weeks</description>
        </group>
        <group group_id="E2">
          <title>Ezetimibe</title>
          <description>ezetimibe, 10 mg/day, for 7 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael H Davidson, MD FACC</name_or_title>
      <organization>Radiant Research</organization>
      <phone>312-494-2220</phone>
      <email>michaeldavidson@radiantresearch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

